PRAX News and Press, Praxis Precision Medicines Inc.

Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route          Potential to expand the addressable market for ulixacaltamide beyond the initial patient population and to enable additional life-cycle management o...

2026-07-01 12:32:55 ET More on the markets U.S. Treasury Debt Jumps By $3.1 Trillion Since Passage Of The One Big Beautiful Bill Act Markets Taking A Break After Epic Quarter; Crude Falls S&P 500 Risks Bull Trap As Stronger U.S. Dollar Threatens Q2 Rally ...

2026-06-29 18:14:20 ET More on Praxis Precision Medicines Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD Elsunersen Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Praxis'...

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug...

2026-06-29 09:15:09 ET Needham analyst issues BUY recommendation for PRAX on June 29, 2026 12:08PM ET. The previous analyst recommendation was Buy. PRAX was trading at $327.79 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2026-06-24 09:45:42 ET More on healthcare stocks IXJ: Healthcare Sector Dashboard For June IHI: Pressured Consumers, Unclear Healthcare Policy, Weak Price Action AI Revolutionizing Biopharma: Faster, Better, Cheaper Weekly ETFs: Five of 11 sectors record...

2026-06-23 13:47:33 ET The last time I spoke about Praxis Precision Medicines, Inc. ( PRAX ), it was with a Seeking Alpha article entitled " Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential ." With respect to this article, I mentioned that the c...

2026-06-23 09:45:20 ET More on Vanguard Mid-Cap Index Fund;ETF, iShares Core S&P Mid-Cap ETF, etc. VO: Mid Caps Now Look Attractive, But Vanguard's $103 Billion ETF Misses The Mark The 1-Minute Market Report, June 7, 2026 SPMD: A 25% Discount To The S&P 500 T...

2026-06-22 09:45:50 ET More on Praxis Precision Medicines Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor Pra...

2026-06-22 09:32:26 ET More on biotech stocks XBI: A "Hidden" ETF Up +70% In 1 Year. IBB: Space Stocks And AI Stealing The Risk-On Show In 2026 Biotech Is Holding Steady In 2026 Syntax Bio expands Series A to $14.4M, adds leadership and board members ...